IN8bio Q2 FY26 net loss narrows to $4.8 million; cash falls to $18 million
INAB•Cash position
Cash totaled $18 million at June 30, 2026, down from $27.09 million at Dec. 31, 2025.
Program updates
ASCO 2026 update showed DeltEx DRI repeat dosing in newly diagnosed GBM with mOS above 19.5 months, mPFS of 13 months; 43% were alive at 24 months.
Management said INB-619 advanced into IND-enabling studies; initial in vivo preclinical data remains targeted for H2 2026.
Quarterly results
IN8bio posted a Q2 net loss of $4.8 million, narrowing from $5.1 million a year earlier; loss per share improved to $0.25 from $1.24.
R&D expense was flat at $2.5 million; G&A expense fell 10% to $2.4 million.
